Investor Relations
|
MNTA - (NASDAQ)
$14.48
- 0.42
|
Sep 2, 2010 3:46 PM ET |
Momenta is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company’s most advanced product candidate, M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox®. Momenta’s first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company’s discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars’ functions in biological processes, with an initial focus in oncology.
Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
View Annual Report and Proxy Material
Recent Releases
Aug 26, 2010
Momenta Pharmaceuticals Provides Litigation Update
Aug 9, 2010
Momenta Pharmaceuticals to Present at the Canaccord 30th Annual Global Growth Conference and the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
View all releases »
